Salix Pharmaceuticals to Present at Credit Suisse Conference
More News related to SLXP
- Salix Pharmaceuticals to Present at Piper Jaffray Conference
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock
- Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
- Salix Pharma (SLXP) Prices 5.5M Share Offering
More News related to Press Releases
- Nihon Kohden America Announces the Auction of Its Latest EEG Technology in Support of the AES Lennox and Lombroso Trust for Epilepsy Research and Training
- Sapiens Announces Payment of Fourth and Final Installment of the Principal Amount of Debentures
- Magic Software Sells Company Office Building for About $5.2 Million in Cash
- Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment
- U.S. Census Bureau Daily Feature for December 6
RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at the 2009 Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 11 at 3:30 p.m. MT/5:30 p.m. ET.
Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.
Salix markets XIFAXAN(R) (rifaximin) tablets 200 mg, OSMOPREP(R) (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, MOVIPREP(R) (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), VISICOL(R) (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO(TM) (mesalamine) extended-release capsules 0.375 g., METOZOLV(TM) ODT (metoclopramide HCl), PEPCID(R) (famotidine) for Oral Suspension, Oral Suspension DIURIL(R) (Chlorothiazide), AZASAN(R) Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC(R) 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC(R) 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT(R) Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT(R) Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, crofelemer and rifaximin for additional indications are under development.
For full prescribing information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, on Salix products, please visit www.salix.com or contact the Company at 919 862-1000.
Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP."
For more information please visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.
Source: Salix Pharmaceuticals, Ltd.
Related Categories
Press ReleasesStocks Mentioned
+0.32Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
